



Gerd W. Clabaugh, MPA
 Director

Kim Reynolds
 Governor

Adam Gregg
 Lt. Governor

DRAFT Notes
Iowa Medical Cannabidiol Advisory Board
May 4, 2018
10:30 a.m. – 3:00 p.m.
Iowa Laboratory Facility – DMACC Campus
2240 DMACC Blvd.
Ankeny, IA

1. Call to Order

Mike McKelvey, Chair

The May 4, 2018, Iowa Medical Cannabidiol Advisory Board Meeting was official called to order at 10:31 am.

2. Roll Call

Mike McKelvey, Chair

Present	Absent
Dr. Ken Cheyne	Dr. Archanda Verma
Dr. Jill Liesveld	
Capt. Mike McKelvey	
Dr. Lonny Miller – via conference call	
Dr. Stephen Richards	
Dr. Bob Schreck	
Dr. Jacqueline Stoken	
Dr. Wendy Zadeh	
Staff	
Heather Adams – Assistant Attorney General	
Sarah Reisetter – Deputy Director	
Randy Mayer – Program Director	
Owen Parker – Program Manager	
Jennifer Caskey – Executive Officer	

3. Approval of Minutes

Mike McKelvey, Chair

a. January 19, 2018, Medical CBD Advisory Board Mtg.

A motion to approve the minutes of the January 19, 2018 Medical Cannabidiol Advisory Board was made by Dr. Zadeh, seconded by Dr. Cheney.

A verbal vote was taken. All members voted in favor. Motion carried.

4. Department Update

Sarah Reisetter, Deputy Director

Sarah Reisetter, Deputy Director provided a departmental update.

- Mr. Owen Parker recently joined the department and will be functioning as the Program Manager for the Office of Medical Cannabidiol. Owen shared a brief overview of this education and background with the meeting participants.
- The department awarded dispensary licenses as of April 1, 2018. MedPharm Iowa was awarded licenses in Windsor Heights and Sioux City. Have A Heart Compassion Care was awarded license in Council Bluffs and Davenport. Iowa Cannabis Company was awarded a license in Waterloo.
- The department received litigation regarding the Davenport dispensary license. The applicant was rejected at the technical review level, denied at the Administrative Law Judge level, and will likely appeal that decision.
- IDPH has posted a second Request for Proposal (RFP) to license a second medical cannabidiol manufacturer. Final applications are due May 30, 2018 with a final licensing decision by July 1. All licensing requirements set forth in the first licensing RFP are again required for a second manufacturer.
- Current card holder information was distributed using map infographics, representing three difference views. The first map, represented by medical condition, shows that almost 1/3 of the current patient care holders suffer from untreatable pain, followed by cancer and seizures. The second map shows primary card applications broken down by the number of approved patient card applications, as well as care giver cards. The third map provides general location information for registered patients in relation to the licensed dispensary locations.
- Work continues on the technology related to implementing the program. IDPH is working closely with our IT vendor in anticipation of having our system ready on time.
- Several bills related to CBD were introduced during the legislative session, with on technically live at the time of this meeting. Common themes among several of the bills are to eliminate the THC cap, add conditions or eliminate specific conditions, allowing doctors to advise, changes to the medical cannabidiol board authority, as well as items related to sales tax. The department's request for fee retention and Department of Public Safety's request for background investigations has been included in the HHS bill.
- The form and quantity recommendations have gone before the Board of Medicine (BOM) at their February meeting. The BOM members were not comfortable with vaporization being an approved form, amending the rules to neublizable forms only. The form and quantity rules should become effective soon.

- The current THC cap will be discussed at the August Medical Cannabidiol Advisory Board meeting, including information on adverse effects. IDPH will seek speakers to address board member request for information on adverse effects.
- Federal Appeals court upheld DEA recommendations that CBD be considered a Schedule 1 product.

5. IT Tracking System Update

Randy Mayer, IDPH

Randy Mayer, Program Director for the Office of Medical Cannabidiol at the Department of Public Health, provided an update on the state's IT Tracking System for the medical cannabidiol program.

- The manufacturing module of the state tracking system is complete.
- Work has begun on the dispensary module of the system.
- The team expects to start the development of the registration module early.
- The overall status of the development of the state's tracking system is slightly ahead of schedule.

6. Public Comment Period

Mike McKelvey, Chair

A number of attendees registered to address the board. A wide variety of subjects were covered during the public comment period. Those addressing the board included:

- Julie Good; patient/advocate shared her personal experience and medical history that has led to her use and support of CBD oils. Ms. Good spoke of the benefits and health improvements she has experienced through the use of CBD and asked the board to expand the approved use of CBD to include other conditions such as depression and anxiety.
- Ashely Decker; patient/advocate shared her personal experience and medical history that has led to her use and support of CBD. Ms. Decker attested to the benefits and improvements that she has experiences in both herself and her mother through the use of CBD products.
- Carl Olsen; lowans for Medical Marijuana clarified that his comments at the January meeting were captured incorrectly. Mr. Olsen stated that he petitioned the Iowa Board of Pharmacy to remove marijuana from a Schedule 1 substance, but did not request it to be classified as a Schedule 2. Mr. Olsen indicated that the board made the decision to reclassify it to a Schedule 2 substance.
- Tom Swegle; CEO of MedCara Pharmaceuticals provided his perspective on moving the issue of THC limits forward, expressed this respect for the work being done by MedPharm Iowa as well as the Advisory Board. Mr. Swegle stated there is an abundance of subject matter experts in the industry who can assist with sharing information on recurrent issues and concerns of the board.
- Roxanne Cogil; Epilepsy Foundation of Iowa shared with the board that they have been receiving numerous of calls from families and patients that have a CBD cards issued under the 2014 bill seeking clarification on the transition to the changes in the 2017 bill. Ms. Cogil suggested the department consider corresponding with physicians that certified epilepsy to

educate them on the changes from 2014 bill to the 2017 bill. Another Also would like to see proper dosing education for minors. Ms. Cogil noted the observation that some legislators are ready to move forward, while others are still resistant, nothing that this is a compassionate use bill, and that they will continue to advocate for a program with various allowable levels.

- Kim Novy; parent advocate shared her experiences with twin daughters who both have epilepsy as well as her mother who suffers from ALS. Ms. Novy advocates for higher levels of TCH for the ALS patients. Ms. Novy expressed her thanks the board of their service, noting that she hears lots of request for education from its members. Ms. Novy stated that although use of CBD is not approved in the US, but that it has been studied since the 70's in Israel, and that there is information out there, all that needs to be done is to look for it, and to remember this is a compassionate use bill.
- Kim Loeffler; owner, Corner Stone Apothecary thanked the board for their service, noting their concerns expressed regarding interactions between doctor and patient. Ms. Loeffler suggested the board members talk to their colleagues that are certifying allowable conditions and know that their patients are using products, have a discussion regarding communications. Ms. Loeffler urged board members to visit dispensaries in other states and ask questions regarding working with patients, noting she visits dispensaries in other states to inform and educate herself.
- Timothy Welty; Chair of Clinical Sciences at Drake spoke to the group to assist with addressing the issues of CBD and concerns that have been expressed. In his experience as a pharmacist involved with epilepsy for over 30 years, he noted that CBD does have some efficacy as well as benefits, but also acknowledged the board's concerns,. Adverse effects and drug interactions should be monitored during the use of CBD, just as they should be with any medication. Mr. Welty questioned the board on what they would do in light of the fact that an FDA panel approved a CBD product for use in treating epilepsy, noting that once it is on the market, any physician can prescribe for any reason. Mr. Welty encouraged board to consider all factors when making recommendations to the legislature.
- Scheril Murray Powell; agricultural and cannabis attorney representing Green Roads. Ms. Murray Powell serves as in-house council for several groups, speaking around the world to educate people on the distinction between hemp and marijuana. Ms. Murray Powell shared information on Green Roads CBD only products, spoke of their rigorous testing of products, their work with various health related groups, and related to the concerns of public and product safe.

7. Dispensary Introductions/Presentations

a. Have A Heart Compassion Care

Ryan Kunkel, Have A Heart Compassion Care

Ryan Kunkel, Founder and CEO along with other representatives from Have A Heart Compassion Care, one of the companies licensed to run dispensaries in Iowa shared a presentation with the board introducing themselves and their company. Information shared included Have a Heart's history, their three part mission, staffing plan and qualifications, staff training and benefits, their medical dispensing plan, both dispensary location layout plans, as

well as patient and public education strategies. Have A Heart has additional dispensary locations in the states of Washington, Oregon, Hawaii, California, as well as Iowa.

b. Iowa Cannabis Company

Tate Kapple, IA Cannabis Company

Tate Kapple, owner, along with several associates from the Iowa Cannabis Company provided a presentation to the board on behalf of their newly licensed dispensary. Information discussed included the desired qualifications they will be seeking in dispensary management staff and technicians, hiring and training tactics, as well as dispensary operations and patient care information.

c. MedPharm Iowa

Lucas Nelson, Kemin/MedPharm IA

Lucas Nelson, General Manager for Kemin Industries and MedPharm Iowa along with other representatives made a presentation to the board on behalf of their newly licensed dispensaries. Information shared included the location of both of the MedPharm dispensaries located in Sioux City and Windsor Heights, staffing plans and qualifications, training plans for staff, education plans for patients and care givers, and overview of day-to-day operations, security measures as well community outreach and education.

8. Manufacturer Update - MedPharm Iowa

Lucas Nelson, Kemin/MedPharm IA

Lucas Nelson, MedPharm Iowa provided an update on the progress being made at MedPharm Iowa's manufacturing facility. Information included the formulations and dosing under development at MedPharm, photos of the physical building's progress, as well as issues and information associated with Iowa's 3% THC cap.

9. Cannabinoids and Epilepsy Presentation

Dr. Michael Ciliberto, U of Iowa

Dr. Michael Ciliberto, University of Iowa - Stead Family Department of Pediatrics, provided a presentation regarding a study he has been participating in regarding the use of cannabinoids in pediatric epilepsy patients. Dr. Ciliberto included information on various cannabinoids, the distribution and elimination of cannabinoids in patients, the two types of cannabinoid receptors in the human brain and how cannabinoids effect these receptors. Dr. Ciliberto included information and data from the study, as well information on the efficacy of CBD use in other types of epilepsy.

10. Petitions to Add/Remove Qualifying Conditions

Sarah Reisetter, Deputy Director

Sarah Reisetter lead a brief discussion with the board regarding the process to submit petitions to add or remove qualifying conditions. Sarah displayed a copy of the regulations regarding petitions, giving a brief overview of things that the board could potentially request to be included with the petitions, discussing what could potentially be provided for education and presentation when reviewing and evaluating a request for add/remove qualifying conditions. The general consensus of the board was to receive copies of submitted petitions as they are received so that members can do their own independent research.

11. Future Meetings Discussion

a. Friday Aug. 3, 2018

b. Friday Nov. 2, 2018

12. Adjourn

Mike McKelvey, Chair

A motion to adjourn the May 4, 2018 Medical Cannabidiol Advisory Board meeting was made by Dr. Richards, seconded by Dr. Stoken.

A verbal vote was taken. Motion carried. The meeting officially adjourned at 3:25 p.m.